| 摘要 |
<p>Novel therapeutic agents useful as inhibitors of HLE are provided. The compounds have structural formula (I) wherein R1 through R9, m, n and p are as defined herein. Methods of using the compounds of formula (I) to inhibit serine proteases and to treat physiological conditions and disease states associated with elevated HLE levels are also provided, as are pharmaceutical compositions containing the compounds.</p> |
